Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness analysis of resective epilepsy surgery in drug-resistant patients: an artificial intelligence data modeling.

Epilepsy & behavior : E&B·2026
Same author

Lessons Learned: Quality Analysis of Optical Coherence Tomography in Neuromyelitis Optica.

Annals of clinical and translational neurology·2025
Same author

Multiscale networks in Alzheimer's disease identify brain hypometabolism as central across biological scales.

PLoS computational biology·2025
Same author

The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2025
Same author

Diffusivity anisotropy signature of slowly expanding lesions predicts progression independent of relapse activity in multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry·2025
Same author

Comorbidities Are Associated With Unfavorable Outcome in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Exploratory Study From the CROCTINO Cohort.

European journal of neurology·2025

Related Experiment Video

Updated: Jun 6, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Biomarkers for multiple sclerosis.

Pablo Villoslada1

  • 1Department of Neurosciences, Institute of Biomedical Research August Pi Sunyer, Hospital Clinic of Barcelona, Barcelona, Spain. pvilloslada@clinic.ub.es

Drug News & Perspectives
|December 15, 2010
PubMed
Summary
This summary is machine-generated.

Developing accurate biomarkers for multiple sclerosis (MS) is crucial for personalized medicine. Validating these biomarkers will improve prognosis and patient quality of life.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Scoring Central Nervous System Inflammation, Demyelination, and Axon Injury in Experimental Autoimmune Encephalomyelitis
08:17

Scoring Central Nervous System Inflammation, Demyelination, and Axon Injury in Experimental Autoimmune Encephalomyelitis

Published on: February 23, 2024

Related Experiment Videos

Last Updated: Jun 6, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Scoring Central Nervous System Inflammation, Demyelination, and Axon Injury in Experimental Autoimmune Encephalomyelitis
08:17

Scoring Central Nervous System Inflammation, Demyelination, and Axon Injury in Experimental Autoimmune Encephalomyelitis

Published on: February 23, 2024

Area of Science:

  • Neurology
  • Biomarker Discovery
  • Personalized Medicine

Background:

  • Multiple sclerosis (MS) presents an unpredictable disease course, leading to significant disability and reduced quality of life.
  • Current prognostic tools for MS, including clinical data and MRI, offer limited accuracy, causing patient concern.
  • There is a need for validated biomarkers to improve the prediction and monitoring of MS progression and treatment response.

Purpose of the Study:

  • To highlight the necessity of developing and validating biomarkers for multiple sclerosis (MS).
  • To emphasize the importance of these biomarkers in personalized medicine for predicting disease course and treatment efficacy.
  • To advocate for a shift in research focus towards clinical validation of biomarkers.

Main Methods:

  • Review of current diagnostic and prognostic methods for MS.
  • Analysis of the limitations in assessing the diagnostic accuracy of potential MS biomarkers.
  • Examination of recent advancements and examples of validated biomarkers in neurological diseases.

Main Results:

  • Existing methods for MS prognosis are insufficient for accurate prediction.
  • Lack of rigorous validation hinders the clinical application of many identified MS biomarkers.
  • Successful validation of biomarkers, such as anti-aquaporin-4 antibodies and optical coherence tomography, demonstrates their potential clinical utility.

Conclusions:

  • Validated biomarkers are essential for advancing personalized medicine in MS.
  • Prioritizing clinical validation over discovery is crucial for translational research in MS.
  • Improved biomarker development and validation will enhance patient care and quality of life in MS.